ood morning, everyone, and nice to see you again after our weeklong sojourn. Such breaks are always welcome, but, of course, are followed by a serious game of catch-up. To cope, we our back to the usual routine of quaffing cups of stimulation and invite you to join us as we dig in for another busy week. On that note, here is the latest batch of tidbits. Hope you have a successful day and do keep in touch. We enjoy tips and documents …

Lannett continues to raise prices on older, off-patent drugs by large amounts, despite an inquiry from the Justice Department and an investigation by the Connecticut attorney general, the New York Times informs us. And at an industry conference last week, Lannett chief executive Arthur Bedrosian maintained the price-hike business model is not over. One Wall Street analyst called the company the “last of the pricing Mohicans.”

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy